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Abstract of thesis 
Incidence of cancer has been increasing exponentially in last one decade. Defined by disorderly and 
uncontrolled growth of cells that severely impairs QOL of patients, cancer therapies face enormous 
challenges. Among the tumor types developed in various organs, lung cancer is one of the most frequent and 
fetal cancer and hence efficacious therapy for these patients is desired. Although several therapies including 
surgery, radiotherapy, and chemotherapy have been developed so far, systemic chemotherapy remains a 
major therapeutic option for lung cancer patients due to the difficulties in its early detection and diagnosis. 
Recent translational research has revealed that existence of key genomic changes for cancer development. 
These are called “oncogenic drivers” and have been identified for lung cancer. In this premises, the molecular 
target agents targeting these driver mutations have been in demand and are expected to provide better 
therapeutic outcome. Among them, drug discovery and development of kinase inhibitors against EGFR are 
remarkable due to their high mutation frequency in non-small cell lung cancer (NSCLC). EGFR-tyrosine 
kinase inhibitor (TKI) has been established as the first choice of treatment for NSCLC harboring EGFR 
mutations. On the other hand, clinical research has demonstrated the existence of EGFR mutations that 
exhibit resistance to treatment with EGFR-TKIs. Especially, the patients harboring EGFR with in-frame 
insertion mutation in exon 20 region has been shown to be poor responders to the existing EGFR-TKI therapy 
 compared to other common mutations. Preclinical studies have revealed that the EGFR-TKIs which have 
acquired FDA approval has a potency to inhibit kinase activity of not only exon 20 insertion mutant-EGFR 
but also wild type (WT) EGFR. Such non-selective response implied to maintain plasma concentrations of 
the compounds low in clinical settings. On the other hand, newer EGFR-TKI, which shows inhibitory activity 
against exon 20 mutant-EGFR while spared WT EGFR, is deemed useful in cancer therapy for these 
population with high unmet medical need.  
The author has conducted compound screening with recombinant human enzymes and genetically 
engineered cell lines. As a result, TAS6417 was identified as an EGFR inhibitor with a unique scaffold. He 
has conducted extensive experiments on inhibitory activity, selectivity, and binding mode in biochemical 
assays. In mobility-shift assay, he confirmed inhibitory activity of TAS6417 against EGFR and its mutants, 
and demonstrated EGFR selectivity in a panel of over 250 kinases. By MS analysis and dissociation assay 
with recombinant enzyme of EGFR D770_N771insNPG (an exon 20 insertion mutation), he found that 
TAS6417 bound covalently to cysteine residue at 797, and showed irreversible or slow-dissociation kinetics. 
Furthermore, the author employed cell lines genetically engineered to express human WT EGFR and exon 
20 insertion mutant-EGFRs, and undertook extensive analysis about cellular potency and mutation selectivity. 
He exposed the cells to TAS6417 that showed potent inhibitory activity against exon 20 insertion mutations 
with a superior mutation selectivity to the representative EGFR-TKIs such as Afatinib and Erlotinib. Based 
on the data, the author revealed that TAS6417 is a potent and selective kinase inhibitor targeting EGFR exon 
20 insertion mutations.  
As the next step, the author conducted in vitro and in vivo experiments with cancer cell lines to assess 
the potential of TAS6417 for anticancer agent. He used a variety of NSCLC cell lines with EGFR mutations 
including exon 20 insertion mutations and human primary keratinocytes of which cell growth is regulated by 
WT EGFR. In cell proliferation assay, he found that TAS6417 inhibited the growth of cancer cells harboring 
EGFR exon 20 insertion mutations. It was mediated by inhibition of phosphorylation of EGFR and its signal 
transduction including MAPK pathway and PI3K pathway, leading to caspase activation in cancer cells. 
While the inhibitory activity of TAS6417 in cancer cell lines was comparable or higher than that of Afatinib, 
its effect on normal keratinocytes was less than Afatinib. The author further evaluated in vivo activity in mice 
subcutaneously implanted with genetically engineered cells expressing the representative EGFR exon 20 
insertion mutations such as D770_N771insSVD and H773_V774insNPH. In these models, Afatinib showed 
minimal or moderate suppression of tumor growth. In contrast, oral administration of TAS6417 exerted a 
significant inhibition of tumor growth associated with intratumoral target inhibition and plasma concentration 
profile over time. It was also seen to achieve a partial to complete remission of tumors in patient derived 
xenograft models, which is more predictable model than xenograft model using cultured cells. In addition, 
in vivo experiment in mouse orthotropic model revealed survival benefit of TAS6417 with a good tolerability. 
Taken together, the author demonstrated that TAS6417 was selectively toxic to cancer cells with EGFR exon 
20 insertion mutation, but its effect to normal cells was moderate. Furthermore, this mutation selective 
characteristics led to a superior antitumor activity to Afatinib in subcutaneous or intrapulmonary implantation 
 model. On the basis of these data, the author proposed TAS6417 as a potential anticancer agent that warrants 
further investigation in clinical trial.  
There are various EGFR mutations such as common mutations (exon 19 deletions and L858R mutation), 
and the third most common mutation is exon 20 insertion mutation, followed by G719X and L861Q 
mutations. The author investigated inhibition spectrum of TAS6417 in EGFR mutations. Combined with the 
results on pharmacodynamics analysis and cell proliferation assay, he found that TAS6417 had cellular 
potency and mutation selectivity against not only common mutations but also G719X and L861Q mutations, 
which differed from other EGFR-TKIs. Consistent with the in vitro property, TAS6417 showed an intensive 
antitumor activity in allograft models such as EGFR G719A and EGFR G719A+T790M. The author provided 
the experimental evidence that TAS6417 had a unique spectrum and selectivity against EGFR mutations. 
 
Abstract of assessment result 
【Review】 
The applicant discovered TAS6417, a new EGFR-TKI, and investigated its pharmacological 
characteristics. Furthermore, the applicant demonstrated that TAS6417 served as irreversible or slow-
dissociation kinetics against EGFR, and inhibited EGFR exon 20 insertion mutations while sparing WT 
EGFR, resulting in selective cytotoxicity to cancer cells. In addition to biological mode of action including 
EGFR signal inhibition and caspase activity induction, he proved anticancer activity of TAS6417, which was 
superior to that of afatinib, in several models such as patient-derived xenograft models and intrapulmonary 
implanted model, related to clinical prediction of cancer response and survival benefit, respectively. The 
applicant also found the unique and broad spectrum to EGFR mutations other than exon 20 insertion 
mutations by in vitro and in vivo experiments. The study passes the criteria of originality, well planning and 
accomplishment. The objective of research is clear and well understood. Experimental models used are well 
suited. Interpretation of the results is clear and reasonable. Data analyses have been done using appropriate 
tools. The results and discussion sections are well written and interpreted.  The study contributes 
significantly in the field of innovation and disease mechanisms with special reference to understanding of 
cancer and its interventions.  
 
【Result】 
The final examination committee conducted a meeting as a final examination on 01/07/2019. The 
applicant provided an overview of dissertation, addressed questions and comments raised during Q&A 
session. All of the committee members reached a final decision that the applicant has passed the final 
examination.  
 
【Conclusion】 
Therefore, the final examination committee approved that the applicant is qualified to be awarded 
Doctor of Philosophy in Disease Mechanism. 
